Details of the Drug

General Information of Drug (ID: DMYQCWT)

Drug Name

Tecartus

Synonyms

Brexucabtagene autoleucel; KTE-X19

Indication

Disease Entry	ICD 11	Status	REF
Mantle cell lymphoma	2A85.5	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

CAR T Cell Therapy

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 7-15 days [2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Mantle cell lymphoma

ICD Disease Classification

2A85.5

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2	FDA Approved Drug Products: Tecartus (brexucabtagene autoleucel) suspension